Big Data Approach Shown to be Effective for Evaluating Autism Treatments

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The findings, recently published in Frontiers in Cellular Neuroscience, have the potential to accelerate the development of successful medical interventions. One of the challenges in assessing the effectiveness of a treatment for autism is how to measure improvement. Currently, diagnosis and evaluating the success of an intervention rely heavily on observations by professionals and caretakers.

"Having some kind of a measure that measures something that's happening inside the body is really important," said Juergen Hahn, systems biologist, professor, and head of the Rensselaer Department of Biomedical Engineering.

Hahn and his team use machine-learning algorithms to analyze complex data sets. That is how he previously discovered patterns with certain metabolites in the blood of children with autism that can be used to successfully predict diagnosis. You can watch Hahn discuss that here.

In this most recent analysis, the team used a similar set of measurements from three different clinical trials that examined potential metabolic interventions. The researchers were able to compare data from before and after treatment, and look for correlations between those results and any observed changes of adaptive behavior.

"What we did here is showed that if you actively try to change concentrations of these metabolites that are being measured, then you will also see changes in the behavior," Hahn said.

Hahn said that this approach was unique in that it analyzed multiple medical markers at the same time, unveiling correlations not seen in the data if each measurement is investigated individually.

"It can speed up the development process because you now have an additional tool that tells you how well a treatment has worked," he said.

Hahn expects this type of approach to become an important component of clinical trials for autism in the future. "Having medical tests that measure quantities directly related to the physiology is important and we hope that they get incorporated into future trials," he said.

Hahn, a member of the Rensselaer Center for Biotechnology and Interdisciplinary Studies, worked on this study with Rensselaer graduate student Troy Vargason, undergraduate student Emily Roth, and Uwe Kruger, who is a professor of practice in the biomedical engineering department.

In addition to developing and successfully testing the first physiological test for autism and this recent work, Hahn has also worked with colleagues to apply his method to determining a pregnant mother's relative risk for having a child with autism spectrum disorder.

Vargason T, Kruger U, Roth E, Delhey LM, Tippett M, Rose S, Bennuri SC, Slattery JC, Melnyk S, James SJ, Frye RE and Hahn J.
Comparison of Three Clinical Trial Treatments for Autism Spectrum Disorder Through Multivariate Analysis of Changes in Metabolic Profiles and Adaptive Behavior.
Front. Cell. Neurosci. 12:503. doi: 10.3389/fncel.2018.00503.

Most Popular Now

Open Call HORIZON-JU-IHI-2022-03-05: Dig…

Mental health disorders represent an area of severe unmet public health need. This has been further negatively impacted by the COVID-19 pandemic, with a substantial increase in the number and...

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Young People Want Trustworthy Mental Hea…

Young people may not be receiving the mental health support they need because of a lack of trust in the smartphone apps that deliver such services, a study suggests. Questions about...

Brain Area Necessary for Fluid Intellige…

A team led by UCL and UCLH researchers have mapped the parts of the brain that support our ability to solve problems without prior experience - otherwise known as fluid...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...